** Shares of cancer test developer Exact Sciences EXAS.O rise ~9% to $60 premarket
** Co's colon cancer screening test receives 16% higher pricing for government-backed Medicare plans for those aged 65 years and older
** Next-generation version of EXAS' non-invasive stool screening test, Cologuard Plus, receives ~16% increase in Medicare reimbursement price, compared with its original version
** "We believe it strengthens the thesis around margin leverage and sets up EXAS to exceed the 20% EBITDA margin by 2027," Piper Sandler analysts say
** Up to last close, stock down ~26% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。